Clinical Trials Browser

Phase 3 × Breast Neoplasms × Gonadotropin-Releasing Hormone × Clear all

NCT04961996 2026-05-22

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

Phase 3 Active not recruiting

4,170 enrolled

Breast

Breast Neoplasms

NCT04546009 2026-05-19

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

Phase 3 Active not recruiting

992 enrolled

Breast

Breast Neoplasms

NCT05306340 2026-04-30

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Phase 3 Active not recruiting

373 enrolled

Breast

Breast Neoplasms

NCT04964934 2026-04-21

SERENA-6

Phase 3 Active not recruiting

315 enrolled

Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

NCT05296798 2026-04-16

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

Phase 3 Active not recruiting

922 enrolled

Breast

Breast Neoplasms

NCT00066690 2026-02-06

SOFT

Phase 3 Completed

3,066 enrolled 15 charts

Breast

Breast Neoplasms

NCT00066703 2026-02-06

TEXT

Phase 3 Completed

2,672 enrolled 14 charts

Breast

Breast Neoplasms

NCT04711252 2025-10-14

SERENA-4

Phase 3 Active not recruiting

1,370 enrolled

Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Skin Diseases

NCT05891093 2024-02-08

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Phase 3 Recruiting

766 enrolled

Breast

Breast Neoplasms

NCT02483767 2017-10-17

POF

Phase 3 Completed

98 enrolled

Breast

Breast Neoplasms

NCT00066807 2016-10-28

PERCHE

Phase 3 Terminated

29 enrolled 6 charts

Breast

Breast Neoplasms

NCT00659373 2016-07-25

Co-SOFT

Phase 3 Completed

86 enrolled 4 charts

Breast

Breast Neoplasms, Fatigue, Sleep Wake Disorders